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1. Introduction 
Approximately 180000 patients undergo pacemaker implantation in the U.S each year [1]. In 
addition, the extreme elderly are the most rapidly growing segment of the U.S. [2,3] and 
pacemakers are commonly implanted in this population. There are reports of pacemaker 
implant complications (generally clinical trials reporting outcomes and incident 
complication rates) and fewer reports of complication rates in the extreme elderly (with a 
persistent exclusion of elderly patients from ongoing clinical trials [4]). A comprehensive 
review of pacemaker implant complications can help improve informed consent in 
preoperative patients. Major and minor complications are defined based upon prior reports 
of device-related complications. [5,6,7,8] Major complications have been defined as death, 
cardiac arrest, cardiac perforation, cardiac valve injury, coronary venous dissection, 
hemothorax, pneumothorax, transient ischemic attack, stroke, myocardial infarction, 
pericardial tamponade, and arterial-venous fistula. Minor complications have been defined 
as drug reaction, conduction block, hematoma or lead dislodgement requiring reoperation, 
peripheral embolus, phlebitis, peripheral nerve injury, and device-related infection. This 
chapter will include discussion of common and uncommon complications of pacemaker 
implantation including associated incidence as well as the associated radiographs and 
common clinical signs of these complications. 
2. Demographics of pacemaker implantation 
From 1993 to 2006, 2.4 million patients received a primary pacemaker and 69,000 pacemaker 
generator changes; women comprised 49% of pacemakers. [1] A review of studies involving 
pacemaker implantation in adults reveals an average age range of 69-86 years with 
approximately 30-40% of patients aged > 80years [9,10]. There is a tendency for higher 
percentage of female patients as age increases; a prior study from our Heart Rhythm Center 
[11] examined pacemaker implant outcomes of extremely elderly patients (>80years) with an 
average implant age of 86 and revealed 61% of implants were performed in females. 
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3. Preprocedural issues 
3.1. Preoperative risk assessment 
As with all surgical interventions requiring anesthesia, recognizing and managing comorbid 
conditions preoperatively helps to mitigate the risks during and immediately after 
pacemaker implantation. The association of heart failure and other structural heart disease 
with cardiac conduction system disease as well as the expanding role of biventricular 
pacemakers specifically indicated for patients with symptomatic congestive heart failure 
means that there is an inherently high risk population of patients frequently served in the 
EP lab. Indeed, CHF increases the risk of all surgery. A decreased LVEF has been found to 
be a predictor of perioperative mortality and morbidity, with the highest risk group being 
those with an EF < 35%; the very patients brought to the lab for resynchronization therapy. 
Pre-procedural management of CHF is not only integral to our practice but vitally important 
to the safety of the procedure. Patients certainly should not be in a state of decompensated 
heart failure. 
3.2. Infection 
Patients who present with systemic infection and positive blood cultures carry the highest 
risk of infection. Infection of implantable devices is one of the most feared complications 
due to the dismal prognosis of untreated infections and risk of device removal. Often we are 
asked to evaluate patients for bradyarrhythmias when they happen to be identified at the 
time of hospitalization for infectious etiologies such as pneumonia and urosepsis as well as 
post cardiac surgery. Pre-implant evaluation for potential sources of infection is critical. The 
estimated rate of infection of permanent endocardial pacing leads is between 1 and 2%, 
however the range is from under 1 percent to greater than 10%. In the PEOPLE study [12], 
device infection requiring removal was correlated to fever within 24 hours of device 
implant, temporary pacing prior to implant, and early reintervention for lead revision or 
hematoma evacuation. The likelihood of infection was nearly doubled by the presence of a 
temporary system. The association with temporary intravenous pacing wires certainly 
implies an association with any indwelling lines including central lines and PICC lines. The 
duration of hospitalization prior to implant was not correlated to higher risk of infection. 
Infections were negatively correlated with de-novo implantation and perioperative 
antibiotic prophylaxis. The latter intervention is considered controversial. Of 28,860 Danish 
patients [13], 3.6% had a lead related complication by 3 months. Risk factors for lead related 
complications included operator inexperience (<25 implants).  
3.3. Procedural management of iodinated contrast agents 
3.3.1. Contrast Induced Nephropathy (CIN) 
Contrast-induced nephropathy is a surprisingly common complication of radio-contrast 
procedures occurring in 15% of cases. It is defined as an absolute increase in creatinine of 
0.5mg/dl (in patients starting under 2) or an increase of 25% of baseline and typically peaks 
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at 48-72 hours after exposure. Creatinine may remain above baseline for 7-14 days. 
Naturally, the best way avoid this complication is to abstain from its use. Single and dual 
lead pacing systems can safely be implanted without the use of contrast at all; Prior data 
from our Heart Rhythm Center [11] revealed that contrast was used in 55 of 92 (59.8%) of the 
pacemaker implantations with a mean intravenous contrast usage of 9.6cc. We often use 
contrast to ensure that the subclavian /axillary venous system is patent and to help guide 
venous access. No contrast was used for generator changes and there were no contrast 
reactions. CRT implantation may require contrast agents to define the coronary (CS) 
anatomy. The vast majority of patients undergoing CRT implants are patients with heart 
failure and its associated comorbidities which very frequently include diabetes and chronic 
kidney disease, therefore a working knowledge and respect for these agents is a necessity. 
We typically use 5cc of iso-osmolar contrast in a 1:1 ratio with NSS and limit CS venography 
to 1 cine if possible. For patients with GFR 30-60ml/min, hydration can usually be achieved 
with 4-6 glasses of water the evening before the procedure. ACE inhibitors, ARBs, and 
NSAIDS can be held the day prior and day of exposure and be resumed 24 hours after 
exposure. For patients with a GFR <30ml/min, the above recommendations should be 
followed with consideration of one or both of the following: 1.) IV hydration using 1L of 
NaCl 0.45% with 50mEq NaHCO3 (1/2 normal saline with 1 amp of sodium bicarbonate) run 
at 1ml/kg/hr for 12 hours. For same day procedures, this can be administered at 3ml/kg/hr 
for 1 hour. 2.) N-acetylcysteine 600mg PO BID the day prior and day of the procedure, 
totaling 4 doses. It must be noted that besides preprocedural hydration, the evidence is not 
conclusive that bicarbonate and acetylcysteine offer additional benefit. Treatment of CIN 
after evident is largely supportive and infrequently requires short-term dialysis.  
CS lead placement can be performed successfully without the use of contrast in patients at 
risk of CIN. [8] CS lead placement at our Heart Rhythm Center without the use of contrast 
begins with CS access by engagement of the CS with a 5French octapolar deflectable 
electrophysiology (EP) catheter or hydrophilic coated 0.035” guidewire that the CS sheath is 
advanced over. Next, a 0.014” guidewire is advanced out distally and the entire CS is probed 
for LV branch vessels in 360 degree fashion; we then work proximally and if no braches are 
found (including very proximal posterolateral “bailout” vessels) then we repeat the process. 
We have demonstrated a 97.3% success rate in LV lead placement with these techniques. [8]  
3.3.2. Contrast allergies 
Immediate anaphylactic reactions including angioedema, bronchospasm, arterial 
hypotension, and shock can occur within minutes of and up to 60 minutes after injection. [14] 
The reported incidence of severe immediate reactions to ionic contrast material (CM) is 0.1-
0.4% and with newer non-ionic, low osmolar or iso-osmolar contrast is 0.02-0.04% but death 
rates from the two materials do not differ. [15] Although incompletely understood, direct 
release of histamine from circulating basophils and eosinophils is probably the primary 
mechanism with IgE mediated mast cell activation (i.e. true allergy) being a much less 
frequent secondary mechanism. A skin testing study showed that only 4% of patients with 
anaphylaxis symptoms had an IgE-mediated mechanism [16]. Delayed reactions from 1 hour 
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to 7 days after injection of CM are T-cell mediated and most typically are skin reactions. [15] 
Patients with even mild anaphylactoid (immediate) reactions should be considered high risk 
in future CM administration. Indeed, a distinction between immediate anaphylactoid and 
non-immediate anaphylactoid reactions may be more clinically relevant than a history of 
mild, moderate, and severe reactions. [17] For purposes of reporting, CM reactions are 
graded 1-3. Grade 1 reactions include one episode of nausea/vomiting or sneezing, grade 2 
reactions being fever/chills, hives, and more severe nausea/vomiting, and grade 3 reactions 
are potentially life-threatening and include angioedema, bronchospasm, laryngospasm, 
pulmonary edema, hypotension, and shock.[18] It is common practice to pre-medicate with 
corticosteroids with or without H1 blockers in patients with a history of moderate or severe 
immediate reactions, despite the fact that randomized trials comparing pretreatment 
strategies are severely lacking. No trials of pre-treatment have tested a steroid-antihistamine 
combination which is the most commonly utilized. [18] In a consensus document published 
by Marcos et al in 2001, 91% of survey respondents administered corticosteroids at least 11 
hours prior to CM administration (though dose frequency varied from 1-3x) and 55% used an 
H1 blocker (diphenhydramine 25-50mg) typically administered once. [14] H2 blockers are 
used, but rarely. In a meta-analysis including 10,011 patients with no history of contrast 
allergy, routine pre-treatment with steroids alone reduced respiratory symptoms after 
contrast injection (frequently ionic, high osmolar) from 1.4% to 0.4% and Grade III symptoms 
from 0.9% to 0.2%. Only a “double dose” steroid regimen reduced Grade III symptoms. [18] 
In this same cohort, there were no “disastrous” consequences. Cutaneous manifestations 
were more often prevented by H1 antagonists and respiratory symptoms show improvement 
with steroid pretreatment. [18] Essential information to be sought from the patient prior to 
administration of contrast is history of previous CM reaction, asthma, renal insufficiency, 
diabetes, and metformin therapy. [19]  
Routine pre-medication of all patients to receive CM is probably not warranted given the 
overall low incidence of a reaction; in fact some have advocated abandoning this procedure 
all together. [18] Patients with a history of severe CM allergy who will likely need IV CM 
injection should probably receive pre-exposure prophylaxis with corticosteroids as well as 
H1 antagonists although strong evidence of benefit is lacking. [16] The likely mechanism for 
the benefit of corticosteroids is a reduction in circulating basophils and eosinophils available 
for direct activation. If CM administration cannot be delayed for 4-6 hours after steroid 
injection, some would omit use and administer only H1 blockers. [19] One can also consider 
the addition of H2 antagonists such as ranitidine but evidence is also lacking. Low or iso-
osmolar contrast such as ioxaglate, iohexol, or ioversol should be used due to the lower 
overall incidence of reactions in patients with a history of asthma or a CM allergy. The 
specific CM causing the prior reaction should be sought and avoided if possible. Cutaneous 
allergic testing can be performed on patients with a history of anaphylactic reactions and a 
“skin test negative” CM should be used but it should be noted that only a fraction of those 
patients will have a positive skin test.[15,18] The ESUR guidelines on prevention of CM 
reactions recommend Prednisone 50mg PO at 13, 7, and 1 hours prior or 
methylprednisolone 32mg orally 12 and 2 hours prior to exposure to CM in addition to 
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diphenhydramine 50mg IV, IM, or PO 1 hour prior to exposure. Despite this, reactions are 
reported in those with prior reactions with corticosteroid pretreatment. 
3.4. Thyroid 
Hypothyroidism has been found in 0.5-0.8% of the population demonstrated by elevated 
serum levels of thyroid-stimulating hormone (TSH) or decreased serum thyroxine levels. 
[20] Undiagnosed (and hence untreated) hypothyroidism can lead to major perioperative 
complications including severe hypotension or cardiac arrest following induction of 
anesthesia, extreme sensitivity to narcotics and anesthetics with prolonged unconsciousness 
and hypothyroid coma following anesthesia and surgery. [20] Ideally, hypothyroidism is 
caught early and thyroxine administered until the patient is euthyroid (generally, 4-6weeks).  
Hyperthyroidism affects approximately 0.2% of men and 2% of women and may cause atrial 
fibrillation, congestive heart failure and thrombocytopenia. [21] In addition, anesthetic 
drugs may be affected by the hypermetabolic state of hyperthyroidism. When total 
intravenous anesthesia is used (often at our center when high frequency jet ventilation is 
used to minimize respiratory motion), propofol infusion rates should be increased to reach 
anesthetic blood concentrations because the clearance of propofol is increased in 
hyperthyroid patients. [21] Supportive management of thyroid crisis includes hydration, 
cooling, inotropes and steroids. Beta-blockade and antithyroid drugs are used as the first 
line of treatment.  
Generally, more thyroid related perioperative complications stem from hypothyroidism as 
opposed to hyperthyroidism however, recognition of either prior to implantation is 
important. Our Heart Rhythm Center generally obtains TSH prior to all device implantation 
and allows 4-6weeks for the patient to become euthyroid prior to proceeding with surgery. 
Emergent cases with thyroid abnormalities require close coordination with anesthesiology 
and will generally be undertaken with general anesthesia. 
4. In-hospital complications 
4.1. Sedation / airway: 
Less than 20% of electrophysiology (EP) programs in the United States exclusively use 
anesthesia professionals for procedural sedation. [22] Minor complications (e.g., atelectasis, 
fever, vascular congestion) may simply be reflective of common postoperative pulmonary 
complications (PPC’s) seen after general anesthesia. Atelectasis can be seen on CT scan in up 
to 90% of patients who are anesthetized [23] and PPC’s have been found to occur in 9.6% of 
patients. [24]. There are data to suggest that patients undergoing invasive EP procedures 
may require deep conscious sedation that often is converted to general anesthesia;[25] thus, 
the use of general anesthesia (including HFJV) during EP procedures may enhance patient 
safety.[26,27] The advantage of general anesthesia was mostly studied in patients 
undergoing complex procedures, such as AF ablation, where precise electroanatomical 
mapping is required. There is not much data supporting the use of general anesthesia 
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(which may increase costs) versus conscious sedation in routine PM implantations. In our 
center, we often use general anesthesia with a laryngeal mask airway to minimize patient 
movement during LV lead implantation. 
4.2. Pneumothorax 
Pneumothorax may occur in as many as 3-4% [28,29] and as few as 0-1% [8,10,11,30,31,32] 
but generally ranges from 1-3% (5,9,33,34,35,36,37] of patients undergoing pacemaker 
implantation. Routine chest radiographs are often performed immediately after pacemaker 
implantation though clinical signs of pneumothorax include hypoxia, shortness of breath, 
pleuritic pain, and hypotension. Figure 1 depicts the radiographic appearance of small, 
medium, and large pneumothoraces. Figure 2 depicts a pseudopneumothorax that resulted 
from external artifact; close review of radiographs by radiologists can limit false-positive 
pneumothorax interpretations. Emergent treatment of pneumothorax includes 
decompression of the pressure tension by thoracentesis or chest tube. Oftentimes, high 
concentrations of inspired oxygen can lead to a resolution of a pneumothorax that comprises 
less than 30% lung volume. (38) This conservative treatment of pneumothorax can reduce 
morbidity and duration of hospitalization and avoid invasive drainage procedures. The 
traditional treatment of patients with traumatic hemo- or pneumo-thoraces has been an 
insertion of a chest tube (CT). CT have larger caliber than pigtail catheters and can cause 
significant trauma during insertion, cause pain, prevent full lung expansion, and worsen 
pulmonary outcomes. [39] Pigtail catheters, smaller and less invasive than chest tubes, have 
been used successfully in patients with nontraumatic pneumothorax. Pigtail catheters have 
demonstrated a non-significant increase (11% vs 4% for CT) in the tube failure rate (defined 
by a requirement for an additional tube or by recurrence requiring intervention) [39]. 
 
 
Figure 1. Examples of Pneumothoraces, Small (A), Medium (B), and Large (C). The edge of the 
pneumothorax is indicated by the arrows. A small left apical pneumothorax is shown in A. A moderate-
sized apical and basilar pneumothorax is shown in B. An almost complete collapse of the left lung is 
shown in C. Please note that examples shown in B and C are from defibrillator implantations. 
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Figure 2. Pseudopneumothorax after removal of temporary internal jugular vein temporary 
pacemaker. Figure A shows an outline (arrows) that appears to indicate a pneumothorax in an 
asymptomatic patient. Repeat CXR indicates that initial findings have resolved (with no intervention) 
and was likely external artifact from gown or skin. 
4.3. Vascular access and hemothorax 
The axillary venous approach has been associated with less frequent pneumothorax and 
subclavian crush syndrome. [40,41] The axillary vein is the continuation of the basilica 
vein that terminates immediately beneath the clavicle at the outer border of the first rib, at 
which point it becomes the subclavian vein. [42] Direct subclavian venous punctures are 
associated with increased rate of pneumothorax [5] while cephalic vein cutdown has been 
associated with the lowest rate of pneumothorax and lead damage. [33,31] Fluoroscopic-
guided, first rib approach to axillary vein access is the most effective means to access the 
vessel while minimizing the risk of pneumothorax. [42] A prior study did examine 
pacemaker implantation complication rates of 632 consecutive implants at a single non-
community institution.[33] They found a 0.6% rate of hemothorax with a substantially 
large incidence of complications experienced by low-volume (<12 implants per year) 
implanters.  
Hemothorax can be caused by pacemaker lead placement (more frequently atrial lead 
perforation) as well as vascular access damage to the subclavian and axillary veins as well as 
the vena cava. Figure 3 depicts a post-implant CXR of a hemothorax from damage to the 
superior vena cava during upgrade of dual chamber pacemaker to biventricular 
defibrillator. This patient experienced pain during passage of the introducer placed over a 
guidewire seen in inferior vena cava with subsequent development of right pleural effusion. 
The injury was believed to have occurred during passage of CS guiding catheter introducer 
over the wire. Recognition of new effusions should be treated as possible procedural related 
hemothorax and surgical consultation is warranted. 
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Figure 3. Hemothorax after Device Implantation (A) From Wire/Sheath Trauma to the Superior Vena 
Cava. The right hemithorax has a layered effusion with blunting of the right costophrenic angle. Image 
B depicts the preoperative radiograph prior to upgrade of pacemaker to defibrillator. 
4.4. Perforation / tamponade 
Perforation (both acute and subacute) has been reported to occur in up to 1% of pacemaker 
implantations. [5,8,10,31,32,35,36,37] In addition, asymptomatic subclinical perforation may 
occur in 15% of patients after device implantation. [43] Symptoms of perforation include 
pleuritic chest pain from pericarditis, diaphragmatic or intercostal muscle stimulation and, 
in the presence of pericardial effusion, patients may develop shortness of breath and 
hypotension as tamponade develops. [44] Others signs/symptoms of perforation include 
right bundle-oid paced QRS morphology (though we have seen RBBB configuration and 
diaphragmatic stimulation in RV apical lead position) or friction rub after implant. If 
perforation is suspected, urgent evaluation of the patient and device function is warranted 
though lead parameters are often within normal limits. [44] Figure 4 shows examples of 
coronary sinus damage that can occur during LV lead implantation. Figure 5 depicts right 
ventricular lead perforations. Cardiac surgery is typically not required for a majority of 
patients diagnosed with cardiac perforation from a pacemaker implantation. Rather, most 
cases can be managed with pericardiocentesis for symptomatic effusions and repositioning 
of the lead in the EP laboratory with close cardiothoracic surgical collaboration. [45,46,44] 
Figure 6 shows a large cardiac silhouette developing after pacemaker implantation that was 
due to large pericardial effusion. The effusion was treated with pericardiocentesis (with no 
evidence of reaccumulation) and did not require lead repositioning. Though perforation and 
subsequent tamponade are infrequent complication of pacemaker implantation, they can be 
responsible for significant patient morbidity and mortality. The risks of perforation cannot 
be underestimated; death from tamponade with subsequent cardiac arrest was responsible 
for 21.8% of the mortality in a worldwide study of perforation after ablation for atrial 
fibrillation. [47]  
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Figure 4. Damage to the coronary sinus during left ventricular lead implantation. Image A depicts a 
dissection/perforation flap and the resulting pericardial staining from engaging the coronary sinus with 
a deflectable electrophysiology recording catheter. Image B shows a similar instance of pericardial 
staining with no focal dissection flap or perforation. Both patients underwent successful LV lead 
implantation at the time. 
 
Figure 5. Examples of Right Ventricular Pacemaker Lead perforation. Images A and B depict an RV 
lead perforation that exits the right ventricular base in A (arrow) and reenters near the right ventricular 
apex in B (arrow). Images C and D depict an right ventricular apical perforation. The lead is seen exiting 
the cardiac silhouette in C (arrow); the lateral view (D) depicts an abrupt change in lead course (arrow) 
that is often seen in right ventricular apical perforations as the lead courses posteriorly in the pericardial 
space. 
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Figure 6. Chest radiograph appearance of large pericardial effusion after RV lead perforation. 
Immediate post-implant CXR (A) shows normal appearance of the cardiac silhouette. Two weeks post-
operative CXR performed because patient reported symptoms of chest pressure (B) shows enlarged 
cardiac silhouette. Patient responded to pericardiocentesis with no lead repositioning. 
4.5. Complications of Left Ventricular (LV) lead placement via the coronary 
sinus 
The emergence of resynchronization therapy has led to an increase in attempts at left 
ventricular lead placement via the coronary sinus. The MIRACLE study program [48] 
reported a 91.6% success rate for LV lead placement, while COMPANION [49] revealed an 
89% success rate for LV lead placement. Another report indicated a similar 92% success rate 
with LV lead placement. [50] Though we counsel our patients on a LV lead placement 
success rate at 88-92%, our center demonstrated a 97% success rate (64 of 66 patients) with 
LV lead placement within the range from 2:30 to 5:30 o’clock in the left anterior oblique 
(LAO) view. [8]  
Complications of biventricular pacing, specifically LV lead placement, include cardiac 
perforation, coronary sinus dissection, electrical trauma (damage to the native conduction 
system), failure to place the lead, dislodgement of the lead, and diaphragmatic stimulation. 
[51] CS dissections or perforations, cardiac perforations, or cardiac vein dissection or 
perforation was reported in 45 of 2078 (2%) in the MIRACLE study program. [48] Figure 4 
depicts damage done to the coronary sinus during LV lead implantation. Loss of LV capture 
and diaphragmatic stimulation leading to interruption of resynchronization therapy has 
been found to occur in 10% and 2% of patients, respectively. [52] The development of new 
LV leads with up to 4 electrodes offer the possibility of numerous pacing vectors that can 
minimize loss of capture and diaphragmatic stimulation. 
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4.6. Arrhythmias (SVT, VT, VF) 
The incidence of sustained atrial, pacemaker-mediated and ventricular rhythm disturbances 
after pacemaker implantation is low. [53]. In patients without prior atrial arrhythmias, 
Jordaens et al found early atrial fibrillation (during the first week) in 2 of 112 patients and 
late atrial fibrillation was seen in seven patients, flutter in one, yielding a total incidence of 
8.9% for 22 months. There were no significant differences with respect to age, etiology, 
electrocardiographic diagnosis, pacing history, or the measured intracardiac P wave 
between the group with and the group without atrial fibrillation. Ventricular fibrillation has 
been reported to occur in 0.1% of all patients undergoing pacemaker implantation and up to 
0.6% of patients aged > 90 years undergoing pacemaker implantation. [10]  
It has been reported that ventricular tachyarrhythmias may be present in 12-31% of patients 
months to years after pacemaker implantation [54] but this may reflect underlying substrate 
issues. However, there are several situations where pacemaker implantation may cause the 
ventricular tachyarrhythmias. These include pacemaker lead irritation of the right 
ventricular inflow [55] and outflow tracts [56], pacemaker stimulus on T wave [57], reentrant 
circuit around endocardial pacemaker lead [58] and bradycardia-dependent VT facilitated 
by long pause caused by myopotential inhibition of a VVI pacemaker. [59] 
4.7. Death  
In-hospital death generally occurs in less than 1% of pacemaker implantations [5,8,10,11,37] 
however there is a concern that death is underreported as some studies do not specifically 
mention perioperative death. [9, 30,31,32, 33] The most common causes of confirmed device 
related in-hospital deaths are perforations (subclavian artery, brachiocephalic trunk, right 
atrium, and right ventricle). The most common cause of non-device related in-hospital 
deaths is myocardial infarction as well as less commonly pulmonary embolism, stroke, heart 
failure, and sepsis. [60]  
4.8. Pocket hematoma 
The incidence of pocket hematoma has been reported at 4.9% and leading to prolonged 
hospitalization in 2.0% of all patients. [61] Reoperation for pocket hematoma was required 
in 1.0% of patients. High-dose heparinization, combined acetylsalicylic acid 
(ASA)/thienopyridine treatment after coronary stenting, and low operator experience 
were independently predictive of hematoma development. [61] In addition, development 
of postoperative hematoma places the patient at elevated risk of device infection. [62] 
There is data to suggest that warfarin causes fewer pocket complications than heparin 
products. Specifically, temporarily interrupting anticoagulation is associated with 
increased thromboembolic events, whereas cessation of warfarin with bridging 
anticoagulation is associated with a higher rate of pocket hematoma and a longer hospital 
stay. [63] 
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4.9. Hospital lengths of stay 
There is little data available on average length of stays post pacemaker implantation. An 
estimate of 2-3days as an average length of stay post implant can be made from the available 
studies. [5,8,11,37] There is evidence that complications cause a substantial increase in the 
length of stay up to 16days. [64] The mean complication costs are $4345 ± $1540 for 
pacemaker lead revision, $24,459 ± $14,585 for pacemaker infection, and $6187 ± $2631 for 
hematoma evacuation. [64]  
5. Subacute post-implant complications (< 30days) 
5.1. Pacemaker and lead function / failures  
Electrocardiographic signs of pacemaker malfunction can be grouped into four categories: 
failure to capture, failure to output, undersensing, and inappropriate pacemaker rate. 
Sensing abnormalities may occur in 3% of patients, failure to capture in 1%, and failure to 
capture and inappropriate pacemaker rate in another 1% of patients. [65] 
5.1.1. Failure to capture 
Loss of capture after pacemaker implantation has many causes: Dislodgement, Elevated 
Thresholds, Inappropriate Lead Placement, Fracture, Insulation Failure, Loose set screw, 
Exit Block (>4 weeks), Perforation, Battery/circuit Failure, Air in Pocket, and 
Metabolic/Drugs (Flecainide). Lead dislodgement, the most common cause of failure to 
capture, [65] has been reported to occur in up to 4-6% of pacemaker implantations [28,35] 
but is generally reported with a 1-3% incidence [5,10,11,30,32,33,34,36,37]. Figure 7A, B, and 
C depicts examples of right atrial, right ventricular, and left ventricular lead dislodgements 
that may result in loss of capture. Lead dislodgements are treated by repositioning in the EP 
laboratory.  
5.1.2. Failure to output 
Failure to pace with no obvious pacemaker output may be caused by battery or circuit 
failure, lead fracture, internal insulation failure, oversensing, loose set screw, or crosstalk. 
Random component failure is rare however, total battery depletion can occur if routine 
pacemaker followup is inadequate. [65] Once initial end-of-life indicators appear, there is 
usually a period of months before the battery reaches a critically low voltage and pacing 
fails. [65] The incidence of pacemaker lead fracture has been reported at 0.1% to 4.2% per 
patient-year and usually occurs adjacent to the generator or near the site of venous access. 
[66] Figure 8 shows a lead fracture discovered at reoperation when patient presented in 
complete heart block with no ventricular capture almost one year from pacemaker implant. 
Figure 9 depicts chest radiograph findings of lead fracture (failure to pace) versus a 
pseudofracture (normal pacing function). Finally, air in header may cause noise oversensing 
(as air released out of header) as shown in Figure 10. Other electrical signals that may cause 
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Figure 7. Right Atrial (A), Right Ventricular (B), and Left Ventricular (C) Leads Before (Pre) and 
After (Post) Dislodgements. Right atrial lead became dislodged after patient twiddled with device. 
Right ventricular lead dislodged by moving more basilar in position (arrow) one day after implant. Left 
ventricular lead dislodged and reseated itself in the body of coronary sinus 3 months after initial 
placement (arrow). 
oversensing include diaphragmatic myopotentials (especially with extending bipolar 
sensing), T waves, P waves, and environmental noise. 
 
Figure 8. Right Ventricular Lead Fracture. Ventricular lead that was fractured one year after 
implantation resulting in failure to pace. Figure 8A shows appearance of right ventricular lead on CXR 
that was suspicious for fracture location (arrow). Figure 8B depicts the intraoperative appearance of 
lead that was likely site of fracture (arrow). 
 
Current Issues and Recent Advances in Pacemaker Therapy 144 
 
Figure 9. The radiograph in A shows a lead fracture that resulted in no capture. The radiograph in B 
depicts a “pseudofracture” where digital frame shift causes artifact to simulate a lead fracture in a 
properly functioning lead. 
 
Figure 10. Noise caused by air in header. Atrial electrogram during device interrogation revealed 
high-frequency noise during sinus rhythm. This patient was not pacemaker dependent so there was no 
failure to pace. 
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5.1.3. Undersensing 
Undersensing of intrinsic cardiac activity results in inappropriate pacing output that 
competes with intrinsic activity. Undersensing is most likely caused by lead dislodgement, 
poor lead position at time of implantation, or an interruption in the insulation of the pacing 
lead. [65] 
5.2. Hospital readmission  
The average rate of hospital readmission within 30 days of pacemaker implant is 4-6%. 
[8,11,28,35] We examined possible factors influencing readmission rates in extreme elderly 
undergoing pacemaker implantation. [11] Overall, increased age and Device Type (e.g., 
single-chamber, dual-chamber, biventricular, generator change) demonstrated a non-
significant trend toward increased readmission rate. The order of decreasing significance in 
a multivariate analysis of readmissions was: Device Type > Age > Creatinine > 
Urgent/Emergent > EF > Sex > Weight.  
5.3. Death 
Early all-cause mortality 30-days after pacemaker implantation has been reported in 0.1-
0.7% of patients. [30,5,36] Death rates may be increased (2%) in the extreme elderly aged > 80 
years due to increased age-related mortality in this group. [11] 
6. Late complications (> 30days)  
6.1. Lead function / failures 
6.1.1. Twiddling 
Originally described in 1968 [67], twiddling refers to patient manipulation of pacemaker can 
or leads that may lead to malfunction. It has a reported incidence of 0.07% in a series of 
17000 patients. [68] Figure 11 depicts lead orientation before and after patient twiddling 
resulted in lead dislodgement. 
6.1.2. Exit block 
Transient disruptions should be excluded first: metabolic and electrolyte abnormalities, 
drug effects, extreme hypothyroidism (myxedema), and cardiac ischemia. There is an 
expected rise in capture threshold in the 2-6 week period after lead placement attributed to 
local inflammation or foreign body reaction at the tip-tissue interface. In the era of epicardial 
and early endocardial leads, this was a much greater concern. Passive fixation endocardial 
leads have, on average, lower stimulation thresholds than active fixation leads due to lack of 
trauma at tissue interface. The degree that the capture threshold increases is markedly 
blunted with steroid eluting endocardial leads which have thus become generally preferred 
for their more favorable delivery characteristics having overcome the problem of  
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Figure 11. A and B. Lead orientation before and after patient twiddling resulted in lead 
dislodgement. Image A depicts the post-implant radiograph baseline lead positioning after 
biventricular defibrillator implant. Image B shows retracted right and left ventricular leads and leads 
tangled in the pocket superior to device can that is rotated. 
higher stimulation thresholds. [69,70] The first randomized trial to compare a standard 
active fixation lead to a similar designed lead with a steroid eluting reservoir was 
reported in 1995. [71] Prior to that time, passive fixation leads were generally preferred 
because the capture threshold was relatively lower than standard active fixation leads. 
The disadvantage to passive fixation leads was an inability to perform atrial mapping, 
unreliable lateral wall stability, and requirement for placement in the atrial appendage 
which may be difficult in patient who have undergone bypass. The most dramatic 
difference in stimulation threshold between steroid eluting leads and standard 
endocardial leads was in the magnitude of increase in the acute phase as well as the 
duration of peak before returning to the chronic threshold. [71] The steroid lead returned 
to chronic capture threshold by week 2 whereas the non-steroid eluting lead remained 
above chronic threshold for 12 weeks. A non-significant increase in atrial lead 
dislodgements occurred with the steroid lead (0% vs 2%, p=0.58). Lower capture 
thresholds allow for lower programmed output to maintain 2x safety margin, ultimately 
improving generator longevity. A rise in capture threshold may occur beyond 6 weeks 
after implantation (chronic phase of lead maturation). As the threshold steadily rises, it 
may exceed the maximum output of the pulse generator, known as exit block. Exit block is 
recognized by high pacing thresholds without radiographic evidence of dislodgement. It 
may be related to inflammation or fibrosis at the electrode-myocardium interface and 
generally presents >4weeks after implantation. [65] Some patients and particularly 
pediatric patients are particularly prone to this phenomena and may lead to multiple lead 
revisions.  
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6.2. Device/lead advisories  
A large multicenter Canadian observational study showed that the complication rate from 
device replacement for an advisory indication was an astounding 9.1%. [72] Of these, 5.9% 
required reoperation and there were 2 deaths. Naturally, the risk of an adverse outcome 
during replacement must be balanced by the risk of death due to device malfunction. 
Pacemakers and defibrillators have saved thousands of lives but as is true of all man-made 
devices, malfunctions have and will continue to occur. In response to a marked increase in 
device advisories in 2005, and to balance alarmism with protection of patients with a high 
risk situation, the Heart Rhythm Society (HRS), utilizing the HRS Task Force on Device 
Performance Policies and Guidelines published guidelines in 2006. [73] Recognizing that 
physicians and patients need timely and accurate information regarding device 
performance, arguably the most important outcome was a call for greater transparency of 
post market analysis and reporting of failures. Device performance is defined as the 
percentage of devices that are in service and functioning appropriately in living individuals 
over time and depends not only on the characteristics of the device but the skill of the 
implanting physician and caregivers following the device. [73] Data compiled from 1990-
2002 from FDA annual reports showed that confirmed device malfunctions leading to 
device explantation were about 0.1-0.9% for pacemakers and 0.7-3.9% for ICDs. [73] 
Although failure rates are low, there is a negative psychological impact on patients who 
have a device which is under advisory, particularly if pacer dependent or if placed for a 
secondary indication.  
To assist in communication from industry to physicians and patients it is proposed that 
terminology be standardized. The term “recall” was changed to “Class I Advisory” which is 
just short of a directive for device replacement because of a reasonable probability that 
malfunction could result in death or significant harm. Class II and class III recalls are 
subsequently referred to as advisory notices (non-life threatening malfunctions) and safety 
alerts (potential malfunctions). This information is disseminated from industry via 
standardized Physician Device Advisory Notifications and Patient Device Advisory 
Notifications which are also available on the manufacturer’s website. Prior experience tells 
us the advisory information should be disseminated to physicians just before patients. 
Advisories should include general information about the malfunction and potential clinical 
implications but should acknowledge that treatment decisions should ultimately be 
determined by patients in consultations with physicians. The situations where device 
replacement is recommended are 1) When mechanism of malfunction is known and likely to 
be recurrent or lead to patient death, 2) The patient is pacer dependant, 3) The device was 
placed for a secondary prevention indication or have received appropriate therapy, 4) The 
device is approaching EOL. Conservative management (enhanced non-invasive and remote 
monitoring) should be considered when 1) The rate of malfunction is very low in non-pacer 
dependant patients or primary prevention without history of appropriate therapy, 2) The 
patient has significant comorbidities or high operative risk even when the risk of device 
malfunction is substantial. 3) Remote monitoring and software reprogramming can 
minimize risk (i.e., non physiologic noise). 
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6.3. Infection 
Up to 60% of patients present with localized infection involving the device pocket whereas 
the remaining patients may present with endovascular infection but no evidence of 
inflammation of the device pocket. [74] Approximately 10% of patients may have 
intracardiac vegetations identified by transesophageal echocardiogram, though can still 
undergo percutaneous lead extraction safely [75]. See Figure 12 for echocardiographic image 
of vegetation adherent to device lead. Generally, the most common pathogen isolated is 
aerobic gram-positive organisms, of which 90% are Staphylococcus species, with a high rate 
of methicillin resistance (~50%). [74] The risk of pacemaker infection is lower than that of 
implantable defibrillators. The presence of epicardial leads and postoperative complications 
at the generator pocket are significant risk factors for early-onset ICD infection, whereas 
longer duration of hospitalization at the time of implantation and chronic obstructive 
pulmonary disease were associated with late-onset ICD infections. [62] In one of the largest 
studies of pacemaker infections [76], repeated operative procedures after the first pacemaker 
implantation were associated with a substantial incremental risk of infection. Female sex, 
older age, and preoperative antibiotics given at the initial implant were associated with a 
lower risk of later infection. The pacing mode, indication for pacing, and complexity of the 
procedure were not independently associated with the risk of later infection. Sixty percent of 
infections have been found to occur within 90days of implant [77] though a large number of 
infections occur during the late follow-up (>1 year post-implant) (76). Generator changes 
and cardiac resynchronization therapy/dual-chamber devices have also been implicated as 
independent predictors of infection. [77]  
 
Figure 12. Transesophageal echocardiographic image of vegetation adherent to pacemaker lead. This 
is a short axis view showing a large, mobile vegetation (encircled) on a right ventricular lead (arrow) in 
a patient with persistent bacteremia. 
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The generally accepted means of device infection treatment is removal of the generator and 
all implanted leads. [78] In a large series of device extractions including 1838 leads [75], 
post-operative 30-day mortality was 10% though no deaths were related directly to the 
extraction procedure. Another series of device extractions reported a 0.5% rate of 
intraprocedural mortality, 4.6% rate of in-hospital mortality, and 2.6% rate of relapsing 
infections within 1 year of reimplantation. [74] 
6.4. Pacemaker syndrome 
Occurs most commonly with single chamber ventricular pacemakers (e.g., VVI or VVIR 
modes) and symptoms are due to loss of atrioventricular synchrony. It must be noted that 
pacemaker syndrome can occur with any pacing mode if AV synchrony is lost. Symptoms 
include malaise, weakness, cannon A waves, CP, cough, confusion, or syncope. 
6.5. Venous thrombosis 
Upper extremity deep venous thrombosis (or stenosis) is uncommon in the general 
population but venous stenosis has been seen in up to 33-64% of patients after implantation 
of pacing leads. [79,80] Statistically significant factors that have been associated with an 
increased risk include previous transvenous temporary leads [80], left ventricular ejection 
fraction <40% [80], systemic infection [81], absence of anticoagulation, use of hormone 
treatment, personal history of venous thrombosis, and presence of multiple leads. [82] 
Symptoms may include shoulder or neck discomfort, ipsilateral arm edema with cyanosis, 
dilated collateral cutaneous veins around the shoulder, or jugular vein distension. [83] 
Venography is considered the gold standard for diagnosis but compressive ultrasonography 
is an effective and economical means of confirming the clinical diagnosis. [83] Treatment 
may include anticoagulation (warfarin and/or heparin), extraction of old nonfunctioning 
lead to create a new venous channel, or venoplasty to reduce venous stenosis or allow the 
implantation of subsequent leads. [83,84] 
7. Predicting risks for procedural complications 
There is some evidence that elderly patients are at increased risk of complications following 
pacemaker implantation. [85] Armaganijan et al [85] found that any early complication 
occurred in 5.1% of patients ≥ 75 years of age compared to 3.4% of patients aged < 75 years. 
The concomitant use of temporary transvenous pacemakers or steroid use within 7days of 
implant have been shown to increase rates of post implant pericardial effusion. [45] Weaker 
predictors of post implant effusions were the use of helical screw ventricular leads, body 
mass index <20, older age, and longer fluoroscopy times. [45] Pneumothorax has been found 
to more common in older, lighter females. [5] A prior study examining predictors of 
complications in extremely elderly patients undergoing pacemaker implantation [11] found 
overall rates of implant complications comparable to data from younger patient populations 
while experiencing a higher 30day all-cause mortality (that may have been attributable to 
elevated all-cause mortality rates in this age-group). Multivariate analysis revealed that 
 
Current Issues and Recent Advances in Pacemaker Therapy 150 
female sex, device type, and urgent/emergent placement demonstrated a non-significant 
trend toward increased rates of complication; increased age and device type demonstrated a 
non-significant trend toward increased readmission rate.  
Higher (>12 implants/year) versus lower volume operators (<12 implants/year) have also 
demonstrated diverging rates of complication. [33] Finally, more complex devices (dual-
chamber vs single ventricular chamber pacemakers) have been associated with higher rates 
of complications. [10,30,31,32,35,37] however, there is data that does not demonstrate 
increased rates of complications in dual-chamber devices. [9,11,34] Finally, it has been 
suggested that physician training (specifically, board-certification or board-eligibility in 
clinical cardiac electrophysiology) may result in lower rates of lead dislodgement. [7,86] 
8. Conclusion 
Major and minor complications occur in approximately 4-7% of patients within 30d of 
pacemaker implantation. [5,10,11,32,36,35] Permanent pacemakers are commonly implanted 
in patients over the age of 65 and this is the most rapidly growing segment of the U.S. 
population. That being said, pacemaker therapy is also associated with an 11-40% risk of 
complications in the pediatric population; the most common complications in this segment 
are pneumothorax, hematoma, and infection. [87] Figure 13 depicts the incidence of the 
most common complications after pacemaker implantation. Prompt recognition and 
treatment of complications after pacemaker implantation is essential for all implanting 
physicians regardless of background. 
 
 
Figure 13. Most Common Complications Seen After Pacemaker Implantation. This figure depicts the 
most common complications seen after pacemaker implantation from available prior. The data are for 
complications seen within 30-42days depending upon the study parameters as referenced. 
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